-
Je něco špatně v tomto záznamu ?
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
O. Schnell, K. Barnard-Kelly, T. Battelino, A. Ceriello, HE. Larsson, B. Fernández-Fernández, T. Forst, JP. Frias, JR. Gavin, F. Giorgino, PH. Groop, HJL. Heerspink, S. Herzig, M. Hummel, G. Huntley, M. Ibrahim, B. Itzhak, S. Jacob, L. Ji, M....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu dopisy
NLK
BioMedCentral
od 2002-12-01
BioMedCentral Open Access
od 2002
Directory of Open Access Journals
od 2002
Free Medical Journals
od 2002
PubMed Central
od 2002
Europe PubMed Central
od 2002
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2002-01-01
Open Access Digital Library
od 2002-01-01
Open Access Digital Library
od 2002-04-01
Medline Complete (EBSCOhost)
od 2002-04-08
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
Springer Nature OA/Free Journals
od 2002-12-01
- MeSH
- chronická renální insuficience * diagnóza epidemiologie terapie MeSH
- diabetes mellitus 2. typu * farmakoterapie MeSH
- diabetes mellitus * farmakoterapie MeSH
- kardiovaskulární nemoci * diagnóza epidemiologie prevence a kontrola MeSH
- krevní glukóza MeSH
- ledviny MeSH
- lidé MeSH
- obezita komplikace MeSH
- selfmonitoring glykemie MeSH
- srdeční selhání * komplikace MeSH
- tepový objem MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- dopisy MeSH
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).
Amsterdam University Medical Centers Amsterdam The Netherlands
Biomea Fusion Redwood City CA United States of America
Center for Diabetes Education EDC Charlotte NC United States of America
Center Internal Medicine Fünf Höfe Munich Germany
Clalit Health Services Haifa Israel
CRS Clinical Research Services Mannheim GmbH Mannheim Germany
Department of Clinical Medicine University of Copenhagen Copenhagen Denmark
Department of Clinical Sciences Malmö Lund University Lund Sweden
Department of Diabetes Central Medical School Monash University Melbourne Australia
Department of Endocrinology Catholic University Leuven Leuven Belgium
Department of Medicine K2 Karolinska Institute Stockholm Sweden
Department of Nephrology University of Helsinki and Helsinki University Hospital Helsinki Finland
Department of Pediatrics Skåne University Hospital Malmö Lund Sweden
Diabetes Leadership Council Indianapolis IN United States of America
Diabetes Patient Advocacy Coalition Tampa FL United States of America
Division of Nephrology and Hypertension University Hospital Fundación Jiménez Díaz Madrid Spain
Emory University School of Medicine Atlanta GA United States of America
Endocrine and Metabolic Consultants Rockville MD United States of America
Faculty of Medicine University of Belgrade Belgrade Serbia
Faculty of Medicine University of Ljubljana Ljubljana Slovenia
Future Evidence Foundation Melbourne Australia
Institute for Diabetes and Obesity Helmholtz Munich Munich Germany
Medical Clinic 3 University Hospital Carl Gustav Carus Dresden Germany
Peking University People's Hospital Xicheng District Beijing China
Practice for Prevention and Therapy and Cardio Metabolic Institute Villingen Schwenningen Germany
School of Public Health Imperial College London London United Kingdom
Sciarc GmbH Baierbrunn Germany
Sheffield Teaching Hospitals Sheffield United Kingdom
Shupyk National Healthcare University of Ukraine Kyiv Ukraine
Southern Health NHS Foundation Trust Southampton United Kingdom
Steno Diabetes Center Copenhagen Herlev Denmark
Technion Faculty of Medicine Haifa Israel
University Medical Center Ljubljana Slovenia
University of Sheffield Sheffield United Kingdom
Weill Cornell Medicine Qatar Qatar Foundation Education City Ar Rayyan Doha Qatar
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24006699
- 003
- CZ-PrNML
- 005
- 20240423155441.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s12933-024-02180-8 $2 doi
- 035 __
- $a (PubMed)38504284
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Schnell, Oliver $u Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany. oliver.schnell@lrz.uni-muenchen.de
- 245 10
- $a CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes / $c O. Schnell, K. Barnard-Kelly, T. Battelino, A. Ceriello, HE. Larsson, B. Fernández-Fernández, T. Forst, JP. Frias, JR. Gavin, F. Giorgino, PH. Groop, HJL. Heerspink, S. Herzig, M. Hummel, G. Huntley, M. Ibrahim, B. Itzhak, S. Jacob, L. Ji, M. Kosiborod, N. Lalic, S. Macieira, RA. Malik, B. Mankovsky, N. Marx, C. Mathieu, TD. Müller, K. Ray, HW. Rodbard, P. Rossing, L. Rydén, PM. Schumm-Draeger, P. Schwarz, J. Škrha, F. Snoek, F. Tacke, B. Taylor, BT. Jeppesen, S. Tesfaye, P. Topsever, T. Vilsbøll, X. Yu, E. Standl
- 520 9_
- $a The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances they represent in reducing the risk of major adverse cardiovascular events (MACE), improving metabolic outcomes, and treating obesity-related heart failure with preserved ejection fraction (HFpEF). A broad audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians participated in online discussions on guideline updates for the management of cardiovascular disease (CVD) in diabetes, heart failure (HF) and chronic kidney disease (CKD); advances in the management of type 1 diabetes (T1D) and its comorbidities; advances in the management of CKD with SGLT2 inhibitors and non-steroidal mineralocorticoid receptor antagonists (nsMRAs); and advances in the treatment of obesity with GLP-1 and dual GIP/GLP-1 receptor agonists. The association of diabetes and obesity with nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis, MASH) and cancer and possible treatments for these complications were also explored. It is generally assumed that treatment of chronic diseases is equally effective for all patients. However, as discussed at the Summit, this assumption may not be true. Therefore, it is important to enroll patients from diverse racial and ethnic groups in clinical trials and to analyze patient-reported outcomes to assess treatment efficacy, and to develop innovative approaches to tailor medications to those who benefit most with minimal side effects. Other keys to a successful management of diabetes and comorbidities, including dementia, entail the use of continuous glucose monitoring (CGM) technology and the implementation of appropriate patient-physician communication strategies. The 10th Cardiovascular Outcome Trial Summit will be held virtually on December 5-6, 2024 ( http://www.cvot.org ).
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a srdeční selhání $x komplikace $7 D006333
- 650 _2
- $a selfmonitoring glykemie $7 D015190
- 650 _2
- $a tepový objem $7 D013318
- 650 _2
- $a krevní glukóza $7 D001786
- 650 12
- $a kardiovaskulární nemoci $x diagnóza $x epidemiologie $x prevence a kontrola $7 D002318
- 650 _2
- $a obezita $x komplikace $7 D009765
- 650 12
- $a chronická renální insuficience $x diagnóza $x epidemiologie $x terapie $7 D051436
- 650 12
- $a diabetes mellitus $x farmakoterapie $7 D003920
- 650 _2
- $a ledviny $7 D007668
- 650 12
- $a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
- 655 _2
- $a dopisy $7 D016422
- 700 1_
- $a Barnard-Kelly, Katharine $u Southern Health NHS Foundation Trust, Southampton, United Kingdom
- 700 1_
- $a Battelino, Tadej $u University Medical Center, Ljubljana, Slovenia $u Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
- 700 1_
- $a Ceriello, Antonio $u IRCCS MultiMedica, Milan, Italy
- 700 1_
- $a Larsson, Helena Elding $u Department of Pediatrics, Skåne University Hospital, Malmö/Lund, Sweden $u Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
- 700 1_
- $a Fernández-Fernández, Beatriz $u Division of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz, Madrid, Spain
- 700 1_
- $a Forst, Thomas $u CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
- 700 1_
- $a Frias, Juan-Pablo $u Biomea Fusion, Redwood City, CA, United States of America
- 700 1_
- $a Gavin, James R $u Emory University School of Medicine, Atlanta, GA, United States of America
- 700 1_
- $a Giorgino, Francesco $u Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro, Bari, Italy
- 700 1_
- $a Groop, Per-Henrik $u Department of Nephrology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland $u Department of Diabetes, Central Medical School, Monash University, Melbourne, Australia
- 700 1_
- $a Heerspink, Hiddo J L $u Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
- 700 1_
- $a Herzig, Stephan $u Division Diabetic Complications, Institute for Diabetes and Cancer, Helmholtz Center Munich, Neuherberg, Germany
- 700 1_
- $a Hummel, Michael $u Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany
- 700 1_
- $a Huntley, George $u Diabetes Leadership Council, Indianapolis, IN, United States of America
- 700 1_
- $a Ibrahim, Mahmoud $u Center for Diabetes Education, EDC, Charlotte, NC, United States of America
- 700 1_
- $a Itzhak, Baruch $u Clalit Health Services, Haifa, Israel $u Technion Faculty of Medicine, Haifa, Israel
- 700 1_
- $a Jacob, Stephan $u Practice for Prevention and Therapy and Cardio-Metabolic Institute, Villingen-Schwenningen, Germany
- 700 1_
- $a Ji, Linong $u Peking University People's Hospital, Xicheng District, Beijing, China
- 700 1_
- $a Kosiborod, Mikhail $u Department of Cardiovascular Disease, Saint Luke's Mid America Heart Institute, University of Missouri-Kansas City School of Medicine, Kansas City, MO, United States of America
- 700 1_
- $a Lalic, Nebosja $u Clinic for Endocrinology, Diabetes and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia $u Faculty of Medicine, University of Belgrade, Belgrade, Serbia
- 700 1_
- $a Macieira, Sofia $u Sciarc GmbH, Baierbrunn, Germany
- 700 1_
- $a Malik, Rayaz A $u Weill Cornell Medicine-Qatar, Qatar Foundation-Education City, Ar-Rayyan, Doha, Qatar
- 700 1_
- $a Mankovsky, Boris $u Shupyk National Healthcare University of Ukraine, Kyiv, Ukraine
- 700 1_
- $a Marx, Nikolaus $u Clinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital, Aachen, Germany
- 700 1_
- $a Mathieu, Chantal $u Department of Endocrinology, Catholic University Leuven, Leuven, Belgium
- 700 1_
- $a Müller, Timo D $u Institute for Diabetes and Obesity, Helmholtz Munich, Munich, Germany $u Walther-Straub Institute for Pharmacology and Toxicology, Ludwig-Maximilians-University Munich (LMU), Munich, Germany
- 700 1_
- $a Ray, Kausik $u School of Public Health, Imperial College London, London, United Kingdom
- 700 1_
- $a Rodbard, Helena W $u Endocrine and Metabolic Consultants, Rockville, MD, United States of America
- 700 1_
- $a Rossing, Peter $u Steno Diabetes Center Copenhagen, Herlev, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Rydén, Lars $u Department of Medicine K2, Karolinska Institute, Stockholm, Sweden
- 700 1_
- $a Schumm-Draeger, Petra-Maria $u Center Internal Medicine Fünf Höfe, Munich, Germany
- 700 1_
- $a Schwarz, Peter $u Medical Clinic III, University Hospital Carl Gustav Carus, Dresden, Germany
- 700 1_
- $a Škrha, Jan $u Third Medical Department and Laboratory for Endocrinology and Metabolism, First Faculty of Medicine, Charles University, Prague, Czech Republic
- 700 1_
- $a Snoek, Frank $u Amsterdam University Medical Centers, Amsterdam, The Netherlands
- 700 1_
- $a Tacke, Frank $u Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte, Berlin, Germany
- 700 1_
- $a Taylor, Bruce $u Diabetes Patient Advocacy Coalition, Tampa, FL, United States of America
- 700 1_
- $a Jeppesen, Britta Tendal $u Future Evidence Foundation, Melbourne, Australia
- 700 1_
- $a Tesfaye, Solomon $u Sheffield Teaching Hospitals, Sheffield, United Kingdom $u University of Sheffield, Sheffield, United Kingdom
- 700 1_
- $a Topsever, Pinar $u Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine, Istanbul, Türkiye
- 700 1_
- $a Vilsbøll, Tina $u Steno Diabetes Center Copenhagen, Herlev, Denmark $u Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
- 700 1_
- $a Yu, Xuefeng $u Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
- 700 1_
- $a Standl, Eberhard $u Forschergruppe Diabetes e. V, Helmholtz Center Munich, Ingolstaedter Landstraße 1, 85764, Neuherberg (Munich), Germany
- 773 0_
- $w MED00008211 $t Cardiovascular diabetology $x 1475-2840 $g Roč. 23, č. 1 (2024), s. 104
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38504284 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423155437 $b ABA008
- 999 __
- $a ok $b bmc $g 2080979 $s 1216466
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 23 $c 1 $d 104 $e 20240319 $i 1475-2840 $m Cardiovascular diabetology $n Cardiovasc Diabetol $x MED00008211
- LZP __
- $a Pubmed-20240412
